Kaken Pharmaceutical Co., Ltd. (TYO:4521)
Japan
· Delayed Price · Currency is JPY 3,753.00
-42.00 (-1.11%)
May 14, 2025, 3:30 PM JST
Kaken Pharmaceutical Revenue
In the fiscal year ending March 31, 2025, Kaken Pharmaceutical had annual revenue of 94.04B JPY with 30.52% growth. Kaken Pharmaceutical had revenue of 18.05B in the quarter ending March 31, 2025, with 3.95% growth.
Revenue
94.04B
Revenue Growth
+30.52%
P/S Ratio
1.53
Revenue / Employee
82.85M
Employees
1,135
Market Cap
143.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 94.04B | 21.99B | 30.52% |
| Mar 31, 2024 | 72.04B | -940.00M | -1.29% |
| Mar 31, 2023 | 72.98B | -3.05B | -4.01% |
| Mar 31, 2022 | 76.03B | 1.06B | 1.41% |
| Mar 31, 2021 | 74.98B | -14.25B | -15.97% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,222.12B |
| Takeda Pharmaceutical Company | 4,581.55B |
| Daiichi Sankyo Company | 1,886.26B |
| HOYA Corporation | 869.37B |
| Terumo | 1,011.15B |
| Otsuka Holdings | 2,393.18B |
| Astellas Pharma | 1,912.32B |
| Olympus | 993.33B |
Kaken Pharmaceutical News
- 5 weeks ago - Top 3 Health Care Stocks That May Crash In Q2 - Benzinga
- 6 months ago - Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - Benzinga